This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Dendreon's Provenge Problems Reach Terminal Stage

Updated with new stock price.

SEATTLE ( TheStreet) -- Dendreon (DNDN): Cue the fat lady.

Ouch! A painful second quarter. Yes, Dendreon announced the big expense cuts, including the shutdown of a Provenge manufacturing facility, for which Wall Street clamored. But (isn't there always a "but" with Dendreon?) Provenge sales in the quarter tanked, falling more than 2% sequentially to $80 million and instantly raising legitimate questions about slowing demand for the prostate cancer immunotherapy in the face of new competition.

Dendreon shares sank 19% to $4.99 in Tuesday mid-day trading amidst multiple analyst downgrades. The last time Dendreon traded this low was in 2009 before Provenge was approved.

Give Dendreon's new CEO John Johnson some credit for rightly calling his company's performance unacceptable. But what followed from there on Dendreon's conference call were a litany of lame excuses and sketchy turnaround plans that only served to underscore Dendreon's precarious perch in the biotech universe.

Amazingly, we are just four days shy of the one-year anniversary of Dendreon's last epic fail. Does anyone remember second quarter 2011 when former CEO Mitch Gold admitted that Provenge's sales growth was being hampered by "cost density" and insurance reimbursement problems?

David Miller of Biotech Stock Research -- a stalwart Dendreon bull -- remembers well but says Monday's issues are far worse:

"Well, that was ugly. To our ears, this conference call was much worse than the one we endured last August," wrote Miller in a research note to his investor clients. "The debacle last August was unexpected to most, but we saw a clear path towards fixing it… Now let's move forward a year. We have a new CEO and, apparently, a brand new commercial team from the top down. We've ping-ponged from a commitment to urology to a commitment to everything. Another 600 people have lost their jobs and were down one manufacturing plant. Worse, Dendreon is shooting for break even instead of a blockbuster. Well, they'll be lucky to hit breakeven after what we heard today."

So, how bad off is Dendreon? So bad that the company actually managed to drive away the one analyst -- Miller -- who knows more about the company than just about anyone and who's stuck with them through the worst of times. That's how bad.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DNDN $0.06 -6.02%
JNJ $101.55 1.21%
MDVN $133.94 1.47%
AAPL $126.37 2.53%
FB $83.20 -0.13%


DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs